|
Piperacillin + tazobactam
|
34%
|
16 000
|
6.1
|
|
Amikacin
|
26%
|
1 000 to 1 500
|
4.1
|
|
Ceftazidime
|
18%
|
2 625 to 4 000
|
5
|
|
Amoxycillin + clavulanic acid
|
17%
|
6 000
|
5.4
|
|
Cefepime
|
14%
|
6 000 to 16 000
|
5.8
|
|
Filgrastim
|
13%
|
0.3
|
4.5
|
|
Fluconazole
|
8%
|
200 to 400
|
6.5
|
|
Ciprofloxacin
|
7%
|
0.3
|
5.5
|
|
Procedure name
|
Patients treated among those developing FN (%)*
|
Average frequency of procedure
|
|
Chest X-ray
|
80%
|
1.2
|
|
Microbiological tests
|
78%
|
2.4
|
|
Abdominal echography
|
7%
|
1.0
|
|
Hospitalization by usage of PP/SP
|
Patients hospitalized among those developing FN (%)
|
Average [range] LOS (days)
|
|
No G-CSF prophylaxis
|
48%
|
4.2 [3-7]
|
|
PP
|
19%
|
1.5 [1-2]
|
|
SP
|
20%
|
3.3 [3-7]
|
